Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Milei Threatens Falkland Oil Firms With Sanctions 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2018 -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Details of the presentation are below:
Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Time: 12:30pm PT / 3:30pm ET
A live webcast of the presentation may be accessed at http://wsw.com/webcast/roth32/eyen/ or on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Lee Roth / Tram Bui
The Ruth Group
Phone: 646-536-7012/7035
E-mail: [email protected]/[email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]
